LABELLING

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING

BOTTLE LABEL

1. NAME OF THE MEDICINAL PRODUCT

Diethylcarbamazine Citrate Tablets 100 mg USP*

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 100 mg diethylcarbamazine citrate (equivalent to 50.9 mg diethylcarbamazine)

3. LIST OF EXCIPIENTS

Lactose monohydrate

4. PHARMACEUTICAL FORM AND CONTENTS

1000 tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C.
Keep the bottle tightly closed in order to protect from light and moisture.
Discard the product 30 days after initial opening.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

* Trade names are not prequalified by WHO. This is the responsibility of the local Drug Regulatory Authority. Throughout this WHOPAR the proprietary name is given as an example only.

11. NAME AND ADDRESS OF THE SUPPLIER

Eisai Co., Ltd.
4-6-10 Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan

12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME)

NT002

13. MANUFACTURER'S BATCH NUMBER

Lot

14. (ADVICE ON) GENERAL CLASSIFICATION FOR SUPPLY

Provided by Eisai to WHO for distribution free of charge
in designated lymphatic filariasis control programmes.

15. INSTRUCTIONS ON USE